File size: 4,638 Bytes
4b632c5 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 |
</=,<= >/=,>= ≤,<= ≥,>= 2nd generation,2nd-generation 5etc times/day,5x/day Absorption t1/2,t1/2\a Adverse drug reaction,ADR Anti-proliferative ,Antiproliferative Anti-rejection ,Antirejection Area under curve,AUC Average concentration,Cavg Body-weight,Body weight Broad spectrum,Broad-spectrum Centi,c Clearance,Cl Compared to,cf Complete response,CR Composition-of-matter,Composition of matter Day,day Days,days Deci,d Decilitre,10ml Dose-limiting toxicities,DLTs Dose-limiting toxicity,DLT double blind,double-blind double masked,double-masked Drug concentration producing 50% maximum response,EC50 Drug concentration that reduces response to another drug by 50%,IC50 early stage,early-stage Effective dose in 50% patients,ED50 Elimination t1/2,t1/2\b Every 10 days,q 10 days Every 3 weeks,q 3wk Extended Access,extended-access Fast track,Fast-track Fat rich,Fat-rich For 3 weeks,x3wk For 5 days,x5 days Forced Expiratory Volume in 1 sec,FEV1 Four times a day,qid Graft versus host,Graft-versus-host Gram,g Half-life,t1/2 Hour,hr Hours,hr International units,IU Intramuscular,im Intravenous,iv Kaplan–Meier curves,KM curves Kilo,k Kilogram,kg Litre/dm3,l Maximum tolerated dose,MTD Micro,\u Microgram,\ug Milli,m Milligram,mg Millilitre/cm3,ml Minute,min Minutes,min Moderate to severe,Moderate-to-severe Molar (NB,Mlar is the same as moles/litre or moles/dm3),M Mole,mol Month,mth Months,mth Nano,n Nanogram,ng Netherlands,The Netherlands Non Randomized,non-randomized Once daily,once-daily Once weekly,1x/wk Open label,open-label Oral,po Orally,po Overall survival,OS Parallel Assignment,parallel-assignment Peak plasma conc.,Cmax per day,/day Pico,p Picogram,pg Placebo-controlled,placebo-controlled Progression-free survival,PFS Proof of concept,proof-of-concept pts,patients Quarter,qtr Randomized,randomized Second half of 2017,2nd half of 2017 Second,s Seconds,s Side effects,side-effects Single Group,single-group ß,beta Stable disease,SD Subcutaneous,sc TEAEs,treatment-emergent adverse events Three times a day,tid Three times a week,3x/wk Time to disease,Time-to-disease Time to disease progression,Time-to-disease progression Time to from admin. to Cmax,Tmax Twice daily,bid Twice per week,2x/wk United Kingdom,The UK United States,The US Units,U Versus,vs Volume of distribution,Vd Week,wk Weeks,wk Well-tolerated,Well tolerated Year,yr Years,yr α,alpha γ,gamma δ,delta σ,sigma participants,subjects The purpose of this study is, The purpose of this study was, The purpose of the study is, The main aim of the study is, The objective of the trial is, The objective of the study is, to find out,to evaluate to demonstrate,to demonstrate to see,to assess to compare,to compare to evaluate,to evaluate to determine,to determine to investigate,to investigate study of, to evaluate phase 1,Phase I phase 2,Phase II phase 3,Phase III phase 1/2,Phase I/II phase 2/3,Phase II/III phase i,Phase I phase ii,Phase II phase iii,Phase III one,1 two,2 three,3 four,4 five,5 six,6 seven,7 eight,8 nine,9 eleven,11 |,/ Placebo comparator,Placebo-controlled Placebo controlled,Placebo-controlled placebo control,Placebo-controlled active comparator,active-controlled open label,open-label 4-week,4 wk 3-Week,3 wk British Approved Name,BAN International Nonproprietary Name,INN US Approved Name,USAN Acute myelogenous leukaemia,AML Acquired immune deficiency syndrome,AIDS Blood pressure,BP Chronic myelogenous leukaemia,CML Chronic Obstructive Pulmonary Disease,COPD Complete response,CR Deep vein thrombosis,DVT Forced Expiratory Volume in 1 sec,FEV1 Graft Versus Host disease,GvHD Heart rate,HR Hepatitis B/C virus,HBV/HCV Herpes simplex virus,HSV Highly active antiretroviral therapy,HAART Human immunodeficiency virus,HIV Inflammatory bowel disease,IBD Irritable bowel syndrome,IBS Multiple sclerosis,MS Myocardial infarction,MI Non-steroidal anti-inflammatory drug,NSAID Osteoarthritis,OA Partial response,PR Rheumatoid arthritis,RA Severe combined immunodeficiency,SCID Simian immunodeficiency virus,SIV Stable disease,SD Systemic lupus erythramatosus,SLE Biological Licence Application,BLA Co-operative research and development agreement,CRADA European Medicine Evaluation Agency,EMEA European Union's Committee for Proprietary Medicinal Products,CPMP Food and Drug Administration,FDA Investigational New Drug,IND Intellectual Property,IP Marketing Authorization Approval,MAA Medicine Control Agency,MCA New Drug Application,NDA Prescription Drug User Fee Act,PDUFA tumor,tumour tumors,tumours leukemia,leukaemia hematological,haematological alzheimer's disease,Alzheimer's disease egfr,EGFR EGFR,EGFR gilead,GILEAD |